Clevidipine for Severe Hypertension in Acute Heart Failure: A VELOCITY Trial Analysis

医学 心力衰竭 心脏病学 内科学 重症监护医学
作者
W. Frank Peacock,Joseph Varón,Ramin Ebrahimi,Lala M. Dunbar,Charles V. Pollack
出处
期刊:Congestive Heart Failure [Wiley]
卷期号:16 (2): 55-59 被引量:38
标识
DOI:10.1111/j.1751-7133.2009.00133.x
摘要

Acute severe hypertension occurs in approximately 50% of patients with acute heart failure (AHF). Clevidipine, the latest-generation dihydropyridine calcium channel blocker, may be useful in the treatment of this patient population. The Evaluation of the Effect of Ultra-Short-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY) trial enrolled 126 patients with systolic blood pressure (SBP) >180 mm Hg for treatment with clevidipine to a patient-specific prespecified initial target range (ITR) of SBP to be achieved within 30 minutes. Of the enrolled patients, 19 had AHF on presentation. Primary end points were the percentage in whom ITR was achieved within 30 minutes and the number whose SBP was below the ITR after 3 minutes of clevidipine infusion. Among the 19 AHF patients in VELOCITY, median time to ITR was 11.3 minutes (95% confidence interval, 7-19). ITR was reached in most patients (94%) within 30 minutes. No patient had hypotension below the ITR, and heart rate remained stable. At 18 hours, 16 of 19 patients had received continuous clevidipine infusion, and their SBP was reduced by mean of 50 mm Hg (25%) from baseline. There were no treatment-related adverse events or adverse events that led to clevidipine discontinuation. Clevidipine safely decreases SBP in AHF and does not cause unexpected hypotension. The results of this post hoc subgroup analysis suggest that clevidipine is safe, well tolerated, and efficacious in AHF patients with hypertension.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
温暖的问候完成签到,获得积分10
1秒前
老登发布了新的文献求助10
1秒前
默默完成签到 ,获得积分10
2秒前
巴豆醇完成签到,获得积分10
2秒前
李博宇发布了新的文献求助10
3秒前
小鹿发布了新的文献求助10
3秒前
chonghuang完成签到,获得积分10
3秒前
月神樂发布了新的文献求助10
3秒前
3秒前
风笛发布了新的文献求助10
3秒前
凡人烦事发布了新的文献求助10
3秒前
3秒前
Maestro_S的应助被心情不错采纳,获得10
3秒前
march的应助被qianzhihe采纳,获得10
4秒前
4秒前
Lv完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
wangjiayi完成签到 ,获得积分20
5秒前
阿白发布了新的文献求助10
5秒前
5秒前
6秒前
Samsara完成签到 ,获得积分10
6秒前
末位牛马完成签到,获得积分10
6秒前
半山完成签到,获得积分10
6秒前
豆豆发布了新的文献求助10
6秒前
极限001的应助被wangzong采纳,获得30
7秒前
7秒前
虚心的雁玉完成签到,获得积分10
7秒前
犹豫白柏发布了新的文献求助10
7秒前
9秒前
9秒前
摩卡完成签到,获得积分10
9秒前
活力板凳发布了新的文献求助10
10秒前
dididi完成签到,获得积分0
10秒前
10秒前
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519